erythromycin cyclic 11,12-carbonate

Erythromycin cyclic 11,12-carbonate is a semi-synthetic macrolide antibiotic derived from erythromycin A. It was developed to address the acid instability of erythromycin, which often leads to poor and erratic oral bioavailability. By forming a cyclic carbonate ester at the 11,12-position of the macrolide ring, the molecule becomes significantly more stable in the acidic environment of the stomach, allowing for more consistent absorption. Like other macrolides, its mechanism of action involves binding to the 23S rRNA of the 50S ribosomal subunit in susceptible bacteria, thereby inhibiting protein synthesis by blocking the translocation of peptide chains. It is primarily indicated for the treatment of respiratory tract, skin, and soft tissue infections caused by Gram-positive bacteria and certain Gram-negative organisms. In China, it is widely manufactured as a generic antibiotic, and it was originally developed in Poland under the name Davercin.

Brand names

Davercin

Other names

erythromycin cyclic carbonatedavercin环酯红霉素